# Inherent Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inherent-biosciences

- Industry: Biotechnology
- Headquarters: Salt Lake City, US
- Website: www.inherentbio.com
- Total disclosed funding: $2.5M
- Latest round: Series A (Sep 6, 2022)
- Investors on record: 8

## About

Based in Utah, US, and founded in 2019 by Andy Olson (CEO), and Kristin Brogaard (CSO), Inherent Biosciences is a diagnostics and therapeutics company that offers epigenetic medicine for complex diseases such as gene dysregulation. In September 2022, Inherent Biosciences raised an undisclosed amount of Series A funding led by Propel Bio Partners, with participation from the Alliance of Angels and Portfolia.

The firm uses its epigenetic platform to detect dysregulation across multiple genes and related pathways to diagnose in early stages and treat diseases like infertility, autoimmune disease, autism, and other complex diseases. The company offers products that help patients suffering from infertility, detect prostate cancer, predict embryo quality, and the need for IVF.

The company intends to use the September 2022 funding to expand its pipeline, scale commercial operations and generate the further seminal data necessary to add SpermQT to the standard of care.

## Funding rounds

- Series A, Sep 6, 2022 — Alliance of Angels, Portfolia, Propel Bio Partners
- Seed, Feb 17, 2021, $2.5M — Kickstart, Park City Angels, Morningstar Foundation, Rhythm VC, MedMountain Ventures

## Investors

- Kickstart (https://capitalatlas.ai/funds/kickstart) — Seed
- Park City Angels (https://capitalatlas.ai/funds/park-city-angels) — Seed
- Morningstar Foundation — Seed
- Rhythm VC (https://capitalatlas.ai/funds/rhythm-vc) — Seed
- MedMountain Ventures (https://capitalatlas.ai/funds/medmountain-ventures) — Seed
- Alliance of Angels (https://capitalatlas.ai/funds/alliance-of-angels) — Series A
- Portfolia (https://capitalatlas.ai/funds/portfolia) — Series A
- Propel Bio Partners (https://capitalatlas.ai/funds/propel-bio-partners) — Series A